A polymorphism but no mutations in the GADD45 gene in breast cancers

Human Genetics

Volumn 97, Issue 4, 1996, Pages 543-547

  Blaszyk, H ^a,c   Hartmann, A ^a,c   Sommer, S S ^b   Kovach, J S ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P53; XENOBIOTIC AGENT;

ARTICLE; ATAXIA TELANGIECTASIA; BREAST CANCER; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; GENETIC CONSERVATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; INTRON; IONIZING RADIATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029930025     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02267084     Document Type: Article

References (39)

1. Canman CE, Wolff AC, Chen CY, et al (1994) The p53-dependent G1-cell cycle checkpoint and ataxia-telangiectasia. Cancer Res 54: 5054-5058
2. Chen CY, Oliner JD, Zhan Q, et al (1994) Interactions between p53 and mdm2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci 91: 2684-2688
3. El-Deiry WS, Kinzler SE, Pietenpol JA, et al (1992) Definition of a consensus binding site for p53. Nat Genet 1: 45-49
4. El-Deiry WS, Harper JW, O'Conner PM, et al (1994) WAF1/CPI1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174
5. Fornace AJ Jr, Nebert D, Hollander MC, et al (1989) Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 9. 4196-4203
6. Fornace AJ Jr, Jackman J, Hollander MC, et al (1992) Genotoxic-stress-response genes and growth-arrest genes. GADD45, MyD. and other genes induced by treatment eliciting growth arrest. Ann N Y Acad Sci 663: 139-153
7. Fritsche M, Haessler C, Brandner G (1993) Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318
8. Gatti RA, Boder E, Vinters HV, et al (1991) Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 70: 99-117
9. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathology. Cancer Res 54: 4855-4878
10. Habuchi T, Kinoshita H, Yamada H, et al (1994) Oncogene amplification in urothelial cancer with p53 gene mutation or mdm2 amplification. J Natl Cancer Inst 86: 1331-1335
11. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329: 1318-1327
12. Hartmann A, Blaszyk H, McGovern RM, et al (1995) P53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 10:681-688
13. Hollander MC, Alamo I, Jackman J, et al (1993) Analysis of the mammalian GADD45 gene and its response to DNA damage. J Biol Chem 268: 24385-24393
14. Kao CC, Yew PR, Berk AJ (1990) Domains required for in vitro association between the cellular p53 and the adenovirus 2E1B 55k proteins. Virology 179: 806-814
15. Kastan MB, Zhan Q, El-Deiry WS, et al (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597
16. Kovach JS, McGovern RM, Cassady JD, et al (1991) Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. J Natl Cancer Inst 83: 1004-1009
17. Lane DP (1992) P53. the guardian of the genome. Nature 358: 15-16
18. Li JY, Laurent-Puig P, Salmon RJ, et al (1995) Polymorphism and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 10: 599-601
19. Lianes P, Orlow I, Zhang ZF, et al (1994) Altered patterns of mdm2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86: 1325-1330
20. Malkin D, Li FP, Strong LC, et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233-1238
21. Momand J, Zambetti GP, Olson DC, et al (1992) The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
22. Oliner JD, Pietenpol JA, Thiagalingam S, et al (1993) Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860
23. Papathanasiou MA, Kerr NCK, Robbins JH, et al (1991) Induction of the GADD45 gene by ionizing radiation in cultured human cells: lack of mediation by protein kinase C. Mol Cell Biol 11: 1009-1016
24. Price BD, Park SJ (1994) DNA damage increases the levels of mdm2 messenger RNA in wtp53 human cells. Cancer Res 54: 896-899
25. Reifenberger G, Liu L, Ichimura K, et al (1993) Amplification and overexpression of the mdm2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739
26. Rodriguez E, Sreekantaiah C, Chaganti, RSK (1994) Genetic changes in epithelial solid neoplasia. Cancer Res 54: 2298-2306
27. Saitoh S, Cunningham J, De Vries EMG, et al (1994) p53 gene mutations in breast cancers in Midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9: 2869-2875
28. Scheffner M, Wemess BA, Huibregtse JM, et al (1990) The E6 oncoprotein encoded by human papilloma-virus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
29. Shiohara M, El-Deiry WS, Wada M, et al (1994) Absence of WAF1 mutations in a variety of human malignancies. Blood 84: 3781-3784
30. Smith ML, Tsuen Chen I, Zhan Q, et al (1994) Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen. Science 266: 1376-1380
31. Sommer SS, Vielhaber EL (1994) Phage promoter-based methods for sequencing and screening for mutations. In: Mullis KB, Ferre F, Gibbs (eds) Polymerase chain reaction. Birkhäuser, Boston, pp 214-221
32. Sommer SS, Cunningham J, McGovern RM, et al (1992) Pattern of p53 gene mutations in breast cancers of women of the Midwestern United States. J Natl Cancer Inst 84: 246-252
33. Soussi T, Legros Y, Lubin R, et al (1994) Multifactorial analysis of p53 alteration in human cancer: a review, Int J Cancer 57: 1-9
34. Stoflet ES, Koeberl DD, Sarkar G, Sommer SS (1988) Genomic amplification with transcript sequencing. Science 239: 491-494
35. Swift M, Morrell D, Massey RB, Chase CL (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325: 1831-1836
36. Tan TH, Wallis J, Levine AJ (1986) Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J Virol 59: 574-583
37. Tishler RB, Calderwood SK, Coleman CN, Price BD (1993) Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53: 2212-2216
38. Zhan Q, Bae I, Kastan MB, Fornance AJ Jr (1994) The p53-dependent gamma-ray response of GADD45. Cancer Res 54: 2755-2760
39. Zhan Q, Carrier F, Fomace AJ Jr (1993) Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 13: 4242-4250